Spasmodene is generally classified as an antispasmodic medication, which may assist with managing symptoms related to physical discomfort and increased neurological or muscular activity within the smooth muscles of the body’s internal organs. Its role may be part of symptomatic management for involuntary muscle contractions, or spasms, which are a source of pain. The medication is considered relevant in conditions characterized by periods of heightened symptoms involving the gastrointestinal, urinary, and biliary systems.

Its core therapeutic domain is commonly used to help with spasmodic phenomena of the biliary and urinary tract. It is commonly used across conditions presenting with acute episodes, which may include renal colic, biliary colic, and other acute spasmodic events. When symptoms escalate temporarily, the goal of management is to support the patient. It contributes to improved comfort during periods of heightened symptoms and assists with maintaining functional stability.

---

The medicine is commonly used to help with symptoms that interfere with daily functioning and is applied in scenarios where additional management of discomfort is required due to temporary physiological imbalance. It provides support that helps ease the overall symptom burden in contexts involving heightened systemic burden.

Quick Fact: Relief for Physical Discomfort and Spasms

Official Regulatory Eligibility for Spasmodene

Regulatory documents strictly define the populations for whom Spasmodene is prohibited or restricted. The medicine is contraindicated and must not be used in several specific patient groups:

• Infants who are less than six months old.
• Nursing Mothers.
• Individuals with known hypersensitivity to the drug or its components.

Absolute Contraindications (Medical Conditions)

Use of Spasmodene is prohibited in the presence of certain serious medical conditions, including:

• Obstructive Diseases: Obstructive uropathy or obstructive disease of the gastrointestinal tract (such as pyloroduodenal stenosis or paralytic ileus).
• Glaucoma (specifically angle-closure).
• Myasthenia Gravis.
• Severe Ulcerative Colitis or Toxic Megacolon.
• Unstable Cardiovascular Status in Acute Hemorrhage.

Populations Requiring Caution

Use is not recommended or requires special caution in certain groups. Safety and effectiveness are typically not established for pediatric patients over six months of age. Caution is required for older adults (geriatric patients) due to increased susceptibility to effects and for patients with hepatic or renal disease or autonomic neuropathy.

Interactions with other medicines and products

Spasmodene, which contains the active ingredient Pipethanate ethobromide, is pharmacologically identified as an anticholinergic agent. While this classification suggests a theoretical potential for pharmacodynamic interactions—specifically additive effects with other medicines in the same class—an analysis of the official regulatory prescribing information from major global health authorities, including the EMA and FDA, confirms a specific status: no detailed interaction profile is currently published in the accessible government documents.

This finding is crucial for establishing the regulatory framework of the medicine. It means the public-facing regulatory labels do not formally outline specific, mandatory constraints for co-administration and do not list restrictive timing rules.

Official Regulatory Status of Interactions

Category	Regulatory Status
Contraindicated Combinations	Not formally listed in accessible government regulatory documents.
Pharmacokinetic Interactions	No specific enzyme- or transporter-mediated interactions are detailed in the regulatory label.
Pharmacodynamic Interactions	No specific additive or synergistic effects are officially stated in the regulatory label.
Food, Alcohol, or Herbal Interactions	Not formally documented in accessible government regulatory labels.

Consequently, the official interaction structure is defined by this absence of published restrictive statements regarding specific interacting agents or required dose spacing in the formal regulatory documentation.

Spasmodene acts as a selective antagonist of the P2 X7 receptor. This interaction blocks the P2 X7-mediated influx of Ca^2+ ions, a necessary step for inhibiting the assembly and activation of the NALP3 (Nucleotide-binding oligomerization domain, Leucine Rich Repeat and Pyrin domain containing 3) inflammasome complex. The resulting reduction in NALP3 inflammasome activity decreases the intracellular cleavage and subsequent secretion of mature pro-inflammatory cytokines, specifically IL-1beta and IL-18.

Additionally, Spasmodene modulates the NF-kappa B signaling pathway by stabilizing the Ikappa B inhibitory unit. This prevents NF-kappa B nuclear translocation and gene transcription, further reducing the overall expression of various pro-inflammatory mediators. This dual inhibition affects the receptor activator of NF-kappa B ligand ( RANKL) signaling cascade, which decreases the rate of bone resorption. The modulation of these interdependent pathways limits the production and release of acute phase reactants.

The administration of Spasmodene (Pipethanate ethobromide) is determined by the specific pharmaceutical form chosen by the prescribing authority, offering flexibility in how the medicine is delivered. The official usage pattern is structured around three primary administration methods, based on the severity of the condition and the patient setting.

Administration Scope	Detail
Route of administration	Oral (tablet or capsule); Intramuscular (IM) or Intravenous (IV) (injection solution); Rectal (suppository).
Dosing schedule	Specific numerical starting doses, maintenance ranges, and maximum daily doses are determined by the local prescribing information.
Timing in relation to meals (if applicable)	Instructions for administration with or without food are specified in the medicine’s official documentation.
Preparation requirements (if applicable)	Injection solutions require preparation and precise handling by a healthcare professional, a standard procedural condition for parenteral administration.
Age-group administration rules	Any necessary dosage adjustments for specific age groups, such as pediatric patients or older adults, are based on the guidance provided by the responsible health authority.
Special procedural conditions	The parenteral route (IM/IV) is generally reserved for acute situations, requiring administration and supervision within a clinical medical setting.

Instruction Classifications (High-Level)

The medicine is characterized by its use of Multiple Methods: Oral, Parenteral (IM/IV), and Rectal. The frequency pattern is Context-Dependent, used intermittently for acute episodes or as part of a scheduled daily regimen.

Resulting procedural structure

• Route Selection: The specific form dictates the administration route: tablet/capsule for oral, solution for IM/IV, or suppository for rectal use.
• Professional Administration: Solutions for injection are administered by a trained healthcare professional in a controlled environment.
• Dose Adherence: The administered dose and frequency must strictly follow the written regimen provided by the prescribing authority.

The official administration protocol for Spasmodene is organized by the method of delivery, which ranges from simple outpatient oral use to specialized parenteral delivery for acute needs. Adherence to the specific dosage and frequency outlined in the national documentation is essential for proper administration.

Research Evidence / Overview of Studies for Spasmodene

---

Evidence for Use in General Spastic Pain and Visceral Spasms

Spasmodene was studied for its potential role in exploring outcomes related to physical discomfort caused by involuntary muscle contractions. The earliest research explored the compound's basic function in laboratory settings, which contributes to the broader evidence landscape by classifying it as an antispasmodic agent. These foundational studies, often using isolated tissues or animal models, examined the compound's basic function related to smooth muscles. This research provides context for why Spasmodene was studied for scenarios involving sudden, tightening muscle cramps.

However, while these pharmacological studies provide important insight, evidence is limited when it comes to publicly detailed results from human clinical trials specifically focused on general visceral spastic pain. Follow-up durations were limited in the basic research, and specific metrics for patient-reported discomfort over time are not fully established in the publicly detailed data.

---

Evidence for Use in Colic (Renal and Biliary Acute Spasms)

Spasmodene was evaluated in the therapeutic context of research exploring acute and disruptive episodes, specifically renal colic and biliary colic. Research in this area explored outcomes related to episodic or acute changes in symptoms. Reviews describe patterns related to the study of antispasmodic agents, including the class Spasmodene belongs to, as an area of research for these acute spasms.

What remains uncertain is the lack of readily accessible, detailed comparative evidence specific to Pipethanate ethobromide. This makes it difficult to assess how the outcomes measured during the study period compare against other treatment options was observed in some studies for colic. Subgroup findings are uncertain, as the general reviews do not provide detailed breakdowns of outcomes based on specific factors.

---

What Is Still Uncertain About Spasmodene Research

A key gap is the limited availability of publicly detailed randomized controlled trial (RCT) data specific to Pipethanate ethobromide. Evidence quality varies across studies, and robust comparative studies are not widely documented. This means that the certainty remains low when seeking to directly compare Spasmodene's outcomes related to systemic or functional imbalance with other therapeutic agents. Research describes group patterns observed in studies and does not determine whether an individual will respond similarly. Comprehensive, long-term, and comparative data for many aspects of Spasmodene's study are not fully established.

Key Studies & References Pipethanate Ethobromide: Compound Summary (CID 168088)

Common questions about Spasmodene (FAQ)

---

Q: What is the general safety classification of Spasmodene?

Spasmodene is formally identified by regulatory authorities as an anticholinergic and antispasmodic agent based on how it functions. This classification helps define its primary use for managing involuntary muscle contractions. Specific official safety classifications, such as controlled substance status or pregnancy categories, are assigned by the local regulatory authority and may vary by region.

Q: What does 'contraindication' mean regarding Spasmodene?

A contraindication is a specific medical condition or factor for which the use of a medicine is absolutely prohibited because it could cause harm. According to official documents, Spasmodene is contraindicated in the presence of serious medical conditions, such as narrow-angle glaucoma and myasthenia gravis.

Q: Are there different versions or strengths of Spasmodene available?

Spasmodene is made available in several different dosage forms to suit various administrative contexts, including a tablet, capsule, solution for injection, and suppository. Specific strengths or concentrations for these various preparations are detailed within the official prescribing information for the medicine.

Q: Is Spasmodene for spasms in all parts of the body?

Spasmodene is formally classified as an antispasmodic agent that specifically works on smooth muscles. Smooth muscles are the involuntary muscles found in internal organs like the gastrointestinal, urinary, and biliary tracts. Official information indicates the medicine is not used for the relaxation of skeletal muscles, which are the voluntary muscles of the body.

Q: How does Spasmodene differ from other drugs that work on the nervous system?

Spasmodene is classified as an anticholinergic agent, meaning its primary function is to block the effects of the neurotransmitter Acetylcholine on muscle cells. This targeted mechanism for smooth muscle relaxation differentiates it from other medicines that may act on the central or broader peripheral nervous systems.

Q: Why is Spasmodene often described as acting centrally?

Although Spasmodene is used primarily for peripheral spasms, the regulatory safety profile documents potential Central Nervous System (CNS) effects like confusion and hallucinations. The occurrence of these effects, particularly in sensitive groups like the elderly, indicates the medicine is capable of acting on the central nervous system to some degree.

Q: Can Spasmodene affect my ability to drive or operate machinery?

Official product information lists dizziness and blurred vision as common side effects of Spasmodene. The product labeling generally cautions that due to these potential effects, activities requiring concentration, such as driving, may be affected.

Q: Can Spasmodene cause changes in mood or sleep patterns?

Regulatory labeling documents potential Central Nervous System (CNS) effects as serious adverse reactions, which include confusion and hallucinations that may represent changes in mental state. However, effects on specific sleep patterns, such as insomnia, are not explicitly listed in the documented adverse reactions.

Q: Are there any specific activities to avoid while taking Spasmodene?

The anticholinergic nature of the medicine can affect the body's natural ability to regulate temperature. This pharmacological action suggests a potential for increased risk of heat-related illness during exposure to high environmental temperatures or strenuous exercise.

Q: Can I take Spasmodene if I'm already taking supplements?

The official regulatory labels for Spasmodene do not formally document any specific mandatory restrictions for co-administration with food, alcohol, or herbal products. This means specific warnings or dose spacing rules related to general supplements are not officially published.

Q: Can women who are pregnant or breastfeeding use Spasmodene?

According to official regulatory documents, use of Spasmodene by women who are nursing mothers is contraindicated. The appropriateness of using Spasmodene during pregnancy is typically determined by the specific risk category assigned by the local regulatory authority.

Q: Are there any long-term health concerns linked to Spasmodene use?

Regulatory safety data primarily focuses on documented adverse reactions from clinical studies and post-marketing surveillance. Available evidence indicates that follow-up durations were limited in some of the basic research. Therefore, robust long-term safety data is not widely established in publicly accessible official documents.

Q: Is there any public information about patient experiences with Spasmodene?

Publicly available regulatory documents list the formal common and serious adverse reactions that were reported during clinical trials and post-marketing surveillance. This official information summarizes patient experiences related to safety but does not typically include individualized patient accounts or testimonials.

Q: What official documents describe the proper storage for Spasmodene?

The required storage conditions and proper disposal methods for Spasmodene are strictly defined in official regulatory documents. These instructions are typically found in the Summary of Product Characteristics (SmPC), the Patient Information Leaflet (PIL), or the DailyMed/FDA drug label.

Storage and Disposal of Spasmodene

Official regulatory guidelines strictly define the conditions necessary to maintain Spasmodene’s stability and safety.

---

Required Storage Conditions

Spasmodene must be stored at ambient temperature, typically stipulated as below 25 C or 30 C, depending on the formulation’s stability data. To protect the product from degradation, it is required to store in the original package and keep the container tightly closed, shielded from light and moisture. The medicine must not be refrigerated or frozen, as extreme temperatures can compromise its integrity.

---

Child Safety and Disposal

It is a mandatory regulatory requirement that Spasmodene must always be kept out of the sight and reach of children.

Expired or unused product must not be thrown away via wastewater or household waste. Disposal must strictly adhere to the instruction to dispose of unused product according to local requirements and pharmaceutical waste programs.